Abbott Laboratories declared that the FDA has given the approval to its Amplatzer Amulet Left Atrial Appendage Occluder device to treat persons with atrial fibrillation (AFib) who are at a higher risk for an ischemic stroke. The device provides prompt closure of the left atrial appendage (LAA), which lowers stroke risk and prevents the immediate requirement for blood-thinning medicines in persons with AFib.
Daiichi Sankyo Company, Limited declared the accomplishment of the primary endpoint in the Japan PRASTRO-III phase 3 study of the antiplatelet agent, prasugrel hydrochloride in thrombotic stroke patients. The clinical study was conducted in a double-blind comparative method to evaluate the effectiveness and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for ischemic stroke recurrence.
Author Credits: Radhika Gupta, Shivam Bhutani